Glaxosmithkline Biologicals Sa

Seqirus UK Limited

Novartis Ag

Yingxia Wen

Andrew John Geall

Philip R Dormitzer

Andrea Carfi

Ethan Settembre

Frederick Porter

Zihao Wang

Francesco Berlanda Scorza

Anders Lilja

Holger Laux

Claudio Ciferri

Irmgard Hofmann

Paola Rinella

Gene Palmer

Ping Wu

Ethan C Settembre

Methods for purifying RNA from a sample, comprising one or more steps of tangential flow filtration, hydroxyapatite chromatography, core bead flow-through chromatography, or any combinations thereof. These techniques are useful individually, but show very high efficiency when used in combination, or when performed in particular orders. The methods can purify RNA in a highly efficient manner without unduly compromising potency or stability, to provide compositions in which RNA is substantially cleared of contaminants. Moreover, they can be performed without the need for organic solvents.

RNA purification methods

The present application discloses stability-indicating potency assays for influenza vaccines.

Influenza potency assays

This invention relates to cytomegalovirus (CMV) proteins suitable for vaccine uses. Provided herein are mammalian host cells, in particular CHO cells, in which the sequence(s) encoding CMV proteins gH, gL, pUL128, pUL130, pUL131 (or a complex-forming fragment thereof) are stably integrated into the genome.

Mammalian cells expressing cytomegalovirus antigens

An isolated human cytomegalovirus (HCMV) membrane protein complex that comprises gH, gL and at least one more HCMV glycoprotein is provided. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. Processes for expressing and purifying such complexes, and subsequent uses of such complexes in immunogenic compositions and vaccines, are also provided.

Complexes of cytomegalovirus proteins

Growing community of inventors

Cambridge, MA, United States of America

Yingxia Wen